138 related articles for article (PubMed ID: 37900244)
1. Combination therapy with toripalimab and anlotinib in advanced esophageal squamous cell carcinoma: A case report.
Chen SC; Ma DH; Zhong JJ
World J Clin Cases; 2023 Sep; 11(27):6579-6586. PubMed ID: 37900244
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of anlotinib plus programmed death-1 blockade versus anlotinib monotherapy as second or further-line treatment in advanced esophageal squamous cell carcinoma: A retrospective study.
Liu Y; Ge Q; Xu S; Li K; Liu Y
Front Oncol; 2022; 12():942678. PubMed ID: 36059654
[TBL] [Abstract][Full Text] [Related]
3. A multi-center, single-arm, phase II study of anlotinib plus paclitaxel and cisplatin as the first-line therapy of recurrent/advanced esophageal squamous cell carcinoma.
Li N; Wu T; Hong YG; Guo YZ; Cheng YF; Ma YJ; Bie LY; Cui DH; Gao XH; Tan BX; Li BS; Luo SX; Wang JS
BMC Med; 2022 Dec; 20(1):472. PubMed ID: 36482345
[TBL] [Abstract][Full Text] [Related]
4. Intracranial complete response to toripalimab and anlotinib in a patient with recurrent brain metastases of small cell lung cancer after failure of second-line maintenance therapy: a case report.
Huang F; Tang J; Lou J; Wang Q; Ma K; Qiao R; Si J; Kang Y; Chen H; Mei J; Wang H; Liu Y; Miao L
Transl Cancer Res; 2022 Sep; 11(9):3337-3342. PubMed ID: 36237231
[TBL] [Abstract][Full Text] [Related]
5. Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double-blind randomized phase 2 trial.
Huang J; Xiao J; Fang W; Lu P; Fan Q; Shu Y; Feng J; Zhang S; Ba Y; Zhao Y; Liu Y; Bai C; Bai Y; Tang Y; Song Y; He J
Cancer Med; 2021 Mar; 10(5):1681-1689. PubMed ID: 33586360
[TBL] [Abstract][Full Text] [Related]
6. Anlotinib Combined with Toripalimab as Second-Line Therapy for Advanced, Relapsed Gastric or Gastroesophageal Junction Carcinoma.
Jiang M; Zhang C; Hu Y; Li T; Yang G; Wang G; Zhu J; Shao C; Hou H; Zhou N; Liu K; Zhang X
Oncologist; 2022 Nov; 27(11):e856-e869. PubMed ID: 35857405
[TBL] [Abstract][Full Text] [Related]
7. Combination anlotinib and toripalimab for an advanced biliary tract cancer patient with high Eastern Cooperative Oncology Group performance status: a case report.
Liu L; Chen B; Tang M; Guo Y; Hou J; Zhou W; Zhu X
Anticancer Drugs; 2024 May; ():. PubMed ID: 38728054
[TBL] [Abstract][Full Text] [Related]
8. [Clinical efficacy of anlotinib plus S-1 as a second-line therapy for recurrent or metastatic esophageal squamous cell carcinoma].
Sun W; Zou X; Zhang W; Hu S; Ge K
Nan Fang Yi Ke Da Xue Xue Bao; 2021 Feb; 41(2):250-255. PubMed ID: 33624599
[TBL] [Abstract][Full Text] [Related]
9. Toripalimab in combination with Anlotinib for unresectable hepatocellular carcinoma after SBRT: A prospective, single-arm, single-center clinical study.
Chen Y; Hong H; Fang W; Zhang X; Luo H; Chen Z; Yu J; Fan W; Chi X; Peng Y
Front Oncol; 2023; 13():1113389. PubMed ID: 37007075
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of toripalimab plus chemotherapy for advanced esophageal squamous cell carcinoma.
Xu K; Wu H; Zhou C; Bao Y; Yu M; Zhang L; Li X
Int J Clin Pharm; 2023 Jun; 45(3):641-649. PubMed ID: 36800145
[TBL] [Abstract][Full Text] [Related]
11. Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma.
He W; Leng X; Mao T; Luo X; Zhou L; Yan J; Peng L; Fang Q; Liu G; Wei X; Wang K; Wang C; Zhang S; Zhang X; Shen X; Huang D; Yi H; Bei T; She X; Xiao W; Han Y
Oncologist; 2022 Feb; 27(1):e18-e28. PubMed ID: 35305102
[TBL] [Abstract][Full Text] [Related]
12. The Sequence of Chemotherapy and Toripalimab Might Influence the Efficacy of Neoadjuvant Chemoimmunotherapy in Locally Advanced Esophageal Squamous Cell Cancer-A Phase II Study.
Xing W; Zhao L; Zheng Y; Liu B; Liu X; Li T; Zhang Y; Ma B; Yang Y; Shang Y; Fu X; Liang G; Yuan D; Qu J; Chai X; Zhang H; Wang Z; Lin H; Liu L; Ren X; Zhang J; Gao Q
Front Immunol; 2021; 12():772450. PubMed ID: 34938292
[TBL] [Abstract][Full Text] [Related]
13. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial.
Wang ZX; Cui C; Yao J; Zhang Y; Li M; Feng J; Yang S; Fan Y; Shi J; Zhang X; Shen L; Shu Y; Wang C; Dai T; Mao T; Chen L; Guo Z; Liu B; Pan H; Cang S; Jiang Y; Wang J; Ye M; Chen Z; Jiang D; Lin Q; Ren W; Wang J; Wu L; Xu Y; Miao Z; Sun M; Xie C; Liu Y; Wang Q; Zhao L; Li Q; Huang C; Jiang K; Yang K; Li D; Liu Y; Zhu Z; Chen R; Jia L; Li W; Liao W; Liu HX; Ma D; Ma J; Qin Y; Shi Z; Wei Q; Xiao K; Zhang Y; Zhang Y; Chen X; Dai G; He J; Li J; Li G; Liu Y; Liu Z; Yuan X; Zhang J; Fu Z; He Y; Ju F; Liu Z; Tang P; Wang T; Wang W; Zhang J; Luo X; Tang X; May R; Feng H; Yao S; Keegan P; Xu RH; Wang F
Cancer Cell; 2022 Mar; 40(3):277-288.e3. PubMed ID: 35245446
[TBL] [Abstract][Full Text] [Related]
14. Toripalimab in Combination With Induction Chemotherapy and Subsequent Chemoradiation as First-Line Treatment in Patients With Advanced/Metastatic Esophageal Carcinoma: Protocol for a Single-Arm, Prospective, Open-Label, Phase II Clinical Trial (TR-EAT).
Wu L; Wang Y; Li B; Wan G; Liang L; Li T; Lang J; Wang Q
Front Oncol; 2022; 12():878851. PubMed ID: 35463350
[TBL] [Abstract][Full Text] [Related]
15. Feasibility and Safety of Anlotinib Monotherapy for Patients with Previously Treated Advanced Esophageal Squamous Cell Carcinoma: A Real-World Exploratory Study.
Zhang S; Wang X; Gu H; Liu JQ
Cancer Manag Res; 2022; 14():1715-1727. PubMed ID: 35592110
[TBL] [Abstract][Full Text] [Related]
16. Case Report: Toripalimab Combined With Anlotinib in a Patient With Metastatic Upper Tract Urothelial Carcinoma After Pembrolizumab Failure.
Zan N; Zhang X; Du L; Lin Z; Yu D; Liu J; Gou F
Front Oncol; 2022; 12():796407. PubMed ID: 35296012
[TBL] [Abstract][Full Text] [Related]
17. Toripalimab combined with definitive chemoradiotherapy in locally advanced oesophageal squamous cell carcinoma (EC-CRT-001): a single-arm, phase 2 trial.
Zhu Y; Wen J; Li Q; Chen B; Zhao L; Liu S; Yang Y; Wang S; Lv Y; Li J; Zhang L; Hu Y; Liu M; Xi M
Lancet Oncol; 2023 Apr; 24(4):371-382. PubMed ID: 36990609
[TBL] [Abstract][Full Text] [Related]
18. Economic evaluation of toripalimab plus chemotherapy compared with chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma in China.
Zheng Z; Fang L; Cai H; Zhu H
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(6):683-690. PubMed ID: 37086175
[TBL] [Abstract][Full Text] [Related]
19. Combined treatment with anlotinib and chemotherapy for advanced esophageal squamous cell carcinoma improved patient survival: a case report.
Yang D; Xu F; Lai X; Li Y; Gao H; Xu Y; Chen R; Ma D
Am J Transl Res; 2020; 12(10):6578-6583. PubMed ID: 33194054
[TBL] [Abstract][Full Text] [Related]
20. Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial.
Zhang G; Yuan J; Pan C; Xu Q; Cui X; Zhang J; Liu M; Song Z; Wu L; Wu D; Luo H; Hu Y; Jiao S; Yang B
EBioMedicine; 2023 Apr; 90():104515. PubMed ID: 36921563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]